World Asset Management Inc boosted its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 2.2% during the second quarter, Holdings Channel reports. The firm owned 2,762 shares of the medical research company’s stock after buying an additional 59 shares during the period. World Asset Management Inc’s holdings in Charles River Laboratories International were worth $279,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently modified their holdings of the company. Cambridge Advisors Inc. purchased a new position in shares of Charles River Laboratories International during the second quarter worth about $202,000. Campbell & CO Investment Adviser LLC purchased a new position in shares of Charles River Laboratories International during the second quarter worth about $217,000. MAI Capital Management purchased a new position in shares of Charles River Laboratories International during the first quarter worth about $224,000. Massmutual Trust Co. FSB ADV raised its position in shares of Charles River Laboratories International by 5.0% in the first quarter. Massmutual Trust Co. FSB ADV now owns 2,739 shares of the medical research company’s stock worth $246,000 after buying an additional 130 shares during the period. Finally, Charter Trust Co. raised its position in shares of Charles River Laboratories International by 11.2% in the second quarter. Charter Trust Co. now owns 3,368 shares of the medical research company’s stock worth $341,000 after buying an additional 338 shares during the period. Institutional investors own 93.79% of the company’s stock.

Shares of Charles River Laboratories International, Inc. (NYSE:CRL) opened at 99.38 on Thursday. Charles River Laboratories International, Inc. has a 12 month low of $67.20 and a 12 month high of $102.32. The firm’s 50-day moving average price is $99.67 and its 200 day moving average price is $92.18. The firm has a market capitalization of $4.73 billion, a P/E ratio of 26.19 and a beta of 1.02.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings results on Wednesday, August 9th. The medical research company reported $1.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.22 by $0.07. Charles River Laboratories International had a net margin of 10.13% and a return on equity of 27.02%. The business had revenue of $469.13 million for the quarter, compared to analyst estimates of $458.25 million. During the same period in the previous year, the business posted $1.20 earnings per share. The business’s revenue was up 8.1% compared to the same quarter last year. Analysts anticipate that Charles River Laboratories International, Inc. will post $5.10 earnings per share for the current fiscal year.

Charles River Laboratories International declared that its Board of Directors has initiated a share repurchase program on Wednesday, May 10th that permits the company to buyback $150.00 million in outstanding shares. This buyback authorization permits the medical research company to purchase shares of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s leadership believes its stock is undervalued.

ILLEGAL ACTIVITY WARNING: This news story was originally posted by Daily Political and is owned by of Daily Political. If you are accessing this news story on another website, it was stolen and republished in violation of US and international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.dailypolitical.com/2017/08/17/charles-river-laboratories-international-inc-crl-shares-bought-by-world-asset-management-inc.html.

A number of brokerages recently issued reports on CRL. Barclays PLC set a $90.00 target price on Charles River Laboratories International and gave the stock a “hold” rating in a research note on Saturday, May 13th. Zacks Investment Research upgraded Charles River Laboratories International from a “hold” rating to a “buy” rating and set a $110.00 target price for the company in a research note on Thursday, August 10th. BidaskClub upgraded Charles River Laboratories International from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, June 20th. Jefferies Group LLC restated a “buy” rating on shares of Charles River Laboratories International in a research note on Wednesday, June 14th. Finally, Citigroup Inc. restated a “neutral” rating and issued a $104.00 target price (up previously from $90.00) on shares of Charles River Laboratories International in a research note on Thursday, May 11th. One analyst has rated the stock with a sell rating, five have issued a hold rating and four have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $96.94.

In other news, insider Davide Molho sold 10,976 shares of the business’s stock in a transaction dated Friday, May 26th. The shares were sold at an average price of $92.84, for a total transaction of $1,019,011.84. Following the transaction, the insider now directly owns 27,525 shares in the company, valued at $2,555,421. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Chairman James C. Foster sold 43,154 shares of the business’s stock in a transaction dated Thursday, June 22nd. The stock was sold at an average price of $100.00, for a total transaction of $4,315,400.00. Following the transaction, the chairman now owns 361,178 shares in the company, valued at $36,117,800. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 81,921 shares of company stock worth $8,017,651. Company insiders own 2.20% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRL).

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.